objectives leukotriene receptor antagonists ltra montelukast used treatment patients asthma aia study evaluated associations clinical requirement ltra genetic polymorphisms alox5 ltc4s cysltr1 tbxa2r genes arachidonic acid cascade management NUMBER aia patients korean population methods asthma control status monitored NUMBER year maintenance medications inhaled corticosteroid oral ltra aia patients classified groups according mean montelukast dose required month maintain asthma control NUMBER year group NUMBER mg n NUMBER group ii n NUMBER group iii NUMBER n NUMBER genetic polymorphisms arachidonic acid cascade determined using extension method results significant difference genotype frequency cysltr1 promoter polymorphism t groups p NUMBER group vs group ii p NUMBER group vs group iii significant associations ltra requirements polymorphisms genes patients variant genotype ct tt t cysltr1 promoter polymorphism showed higher expression level common genotype cc conclusion findings indicate cysltr1 promoter polymorphism useful genetic marker predicting ltra requirements management aia patients line aspirin intolerant cox NUMBER long term NUMBER NUMBER single base 634c 634c long term montelukast month mg month mg month